# Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

> **NCT05726370** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 28 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer
- Resectable Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Second Primary Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** CISPLATIN
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05726370
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-20
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-05-20
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726370, "Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05726370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*